Davide Bonazzi
Illustrator
From this contributor
Company on brink takes psilocybin to trial for fragile X syndrome
The phase 2A trial has its detractors despite positive animal results and is being sponsored by a company that is struggling financially.
Company on brink takes psilocybin to trial for fragile X syndrome
Explore more from The Transmitter
Psychedelics research in rodents has a behavior problem
Simple behavioral assays—originally validated as drug-screening tools—fall short in studies that aim to unpack the psychedelic mechanism of action, so some behavioral neuroscientists are developing more nuanced tasks.
Psychedelics research in rodents has a behavior problem
Simple behavioral assays—originally validated as drug-screening tools—fall short in studies that aim to unpack the psychedelic mechanism of action, so some behavioral neuroscientists are developing more nuanced tasks.
New organoid atlas unveils four neurodevelopmental signatures
The comprehensive resource details data on microcephaly, polymicrogyria, epilepsy and intellectual disability from 352 people.
New organoid atlas unveils four neurodevelopmental signatures
The comprehensive resource details data on microcephaly, polymicrogyria, epilepsy and intellectual disability from 352 people.
Can neuroscientists decode memories solely from a map of synaptic connections?
Five experts discuss the progress, possibilities and hurdles of decoding a “nontrivial” memory from an organism just by analyzing its brain connectivity patterns.
Can neuroscientists decode memories solely from a map of synaptic connections?
Five experts discuss the progress, possibilities and hurdles of decoding a “nontrivial” memory from an organism just by analyzing its brain connectivity patterns.